Safety and immunogenicity of BNT162b2 in ART-treated PWH
Clicks: 1
ID: 318100
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #186 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background People with human immunodeficiency virus (PWH) are at increased risk of severe COVID-19 and are recommended for priority vaccination. We investigated the safety and immunogenicity of a two-dose regimen of the mRNA vaccine BNT162b2 in PWH on antiretroviral therapy (ART). Methods Safety, reactogenicity and immunogenicity data were obtained from PWH on ART ≥16 years enrolled in the Phase 1/2/3 BNT162-02 trial/C4591001 (NCT04368728) between September and November 2020, which randomized participants (1:1) to receive BNT162b2 or placebo. Immunogenicity was also investigated in a sub-study of the open-label Phase 1/2 BNT162-01 trial (NCT04380701) in PWH 18–85 years and age- and sex- matched HIV-negative controls enrolled February to March 2021. Results In total, 201 PWH were included from the BNT162-02 trial. Higher rates of local and systemic reactions were reported during the seven days following both doses by participants administered BNT162b2 vs participants administered placebo, most notably pain at injection site, fatigue, headache, and chills. Most reactions were mild-to-moderate in severity. No serious adverse events occurred up to 1-month post-Dose 2. Spike protein-binding and SARS-CoV-2 neutralizing antibody responses were elicited in participants who received BNT162b2 and remained above prevaccination baseline levels through 6 months post-Dose 2. In the BNT162-01 trial, all PWH (N = 15) seroconverted, with BNT162b2-induced SARS-CoV-2 neutralization titers and longitudinal T-cell responses similar to those observed in the HIV-negative cohort. Conclusions Primary two-dose vaccination with BNT162b2 in PWH was well tolerated and immunogenic with sustained responses up to 6 months, supporting vaccination in this priority population.
| Reference Key |
openalex_W7165485583
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Essack Mitha, Mezgebe Berhe, Judith A. Aberg, Christopher Lucasti, Fadi Chalhoub, Nicholas Kitchin, Isabel Vogler, Stephen Lockhart, Sina Fuchs, Jasmin Quandt, William C. Gruber, Chris Webber, Marie-Cristine Kühnle, Alexander Muik, Bonny Gaby Lui, Maria J G T Vehreschild, Christoph Stephan, Meghan Bushway, Xia Xu, Todd Belanger, James Trammel Price, S. Liebscher, Ruth Bailey, Susan Mather, Elizabeth M. Adams, Svetlana Shpyro, Eleni Lagkadinou, Özlem Türeci, Kena A. Swanson, Uğur Şahin, Alejandra Gurtman |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag310
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.